Should you sell your OptimizeRx stock?

Roth Capital Markets analyst Richard Baldry says OptimizeRx (OptimizeRx Corporation Stock Quote, Chart, News, Analysts, Financials NASDAQ:OPRX) reported results largely in line with expectations on revenue but delivered a strong profitability beat due to cost controls.

In a March 6 sales analysis, Baldry maintained a “Buy” rating on OptimizeRx while lowering his 12-month price target to $18.00 following the company’s fourth-quarter results.

OptimizeRx reported Q4 2025 revenue of $32.2-million, roughly in line with Baldry’s $31.8-million estimate and flat year-over-year. However, Adjusted EBITDA reached a record $12.0-million, nearly double Baldry’s $6.5-million forecast and 35% above the prior quarterly record set in Q4 2024.

Pro forma earnings per share also significantly exceeded expectations at $0.45, nearly double Baldry’s $0.24 estimate.

Baldry said the revenue slowdown reflects headwinds affecting pharmaceutical industry marketing budgets following a policy initiative introduced by the Donald Trump administration that seeks to tie U.S. drug prices to the lowest prices offered globally.

As pharmaceutical companies navigate negotiations related to the “most favoured nation” pricing framework, Baldry said many have curtailed discretionary marketing spending and shortened contract durations, creating near-term pressure for OptimizeRx.

“This leaves OPRX’s ability to influence revenues severely curtailed near-term,” Baldry said.

The company expects those headwinds to persist through the first half of 2026. Baldry now forecasts first-quarter revenue declining about 12.5% year-over-year and second-quarter revenue falling roughly 10%.

As a result, he lowered his 2026 revenue forecast to $114.0-million from $123.8-million previously, in line with the upper end of management’s revised guidance range of $109-million to $114-million.

Despite the weaker revenue outlook, Baldry increased his earnings expectations following the strong margin performance.

“With well-controlled costs likely sustainable… we view OPRX’s higher core earnings engine as likely to persist,” he said.

Baldry now forecasts 2026 Adjusted EBITDA of $24.8-million and pro forma EPS of $1.01, up from prior estimates of $22.0-million and $0.90, respectively.

While near-term revenue growth may remain volatile, Baldry said OptimizeRx’s profitability improvements and recently authorized $10-million share buyback should help support the stock during the current period of uncertainty.

-30-